无时无刻的疗法:临床实践中维生素K对抗剂的心脏指示
Eva K Kempers1, Melanie Jacqueline J Acampo-de Jong2, Hugo Ten Cate3
1Haematology, Erasmus Medical Center, Rotterdam, The Netherlands.
Heart (British Cardiac Society)
|February 27, 2026
概括
维生素K对抗剂 (VKA) 对于特定的心血管疾病,如机械心脏和心脏动与心肌狭窄,尽管直接口服抗凝剂 (DOAC) 的有效性仍然至关重要. 本综述详细介绍了VKA的症状和管理.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗凝药对于心血管疾病管理至关重要.
- 直接口服抗凝剂 (DOACs) 在心房动 (AF) 和静脉血栓栓塞症中有效预防中风.
- 然而,维生素K抗剂 (VKA) 在特定患者群体中更受青或提供不确定的DOAC益处.
研究的目的:
- 在需要VKAs的情况下,审查心脏指示和患者特征.
- 讨论VKA治疗的管理原则.
主要方法:
- 随机对照试验的文献综述和临床指南.
- 对特定患者群体和心脏病状况的分析.
主要成果:
- VKA适用于机械心脏门,中度至重度心肌狭窄的AF,左心室/心房血栓以及脆弱的老年患者.
- 在这些特定的场景中,DOAC的好处是不确定的.
结论:
- 在心血管疾病管理中,VKA仍然至关重要.
- 了解VKA的征兆和管理对于患者的护理至关重要.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K


